Last reviewed · How we verify

Ondansetron orodispersible film once

Chongqing University Cancer Hospital · FDA-approved active Small molecule

Ondansetron orodispersible film once is a 5-HT3 receptor antagonist Small molecule drug developed by Chongqing University Cancer Hospital. It is currently FDA-approved for Prevention of nausea and vomiting induced by chemotherapy, Prevention of postoperative nausea and vomiting, Prevention of radiation-induced nausea and vomiting.

Ondansetron blocks serotonin 5-HT3 receptors on chemoreceptor trigger zone and vagal afferent nerves to prevent nausea and vomiting.

Ondansetron blocks serotonin 5-HT3 receptors on chemoreceptor trigger zone and vagal afferent nerves to prevent nausea and vomiting. Used for Prevention of nausea and vomiting induced by chemotherapy, Prevention of postoperative nausea and vomiting, Prevention of radiation-induced nausea and vomiting.

At a glance

Generic nameOndansetron orodispersible film once
SponsorChongqing University Cancer Hospital
Drug class5-HT3 receptor antagonist
Target5-HT3 receptor
ModalitySmall molecule
Therapeutic areaOncology / Gastroenterology
PhaseFDA-approved

Mechanism of action

Ondansetron is a selective antagonist of serotonin 5-HT3 receptors, which are located in the chemoreceptor trigger zone and on vagal afferent fibers in the gastrointestinal tract. By blocking these receptors, it prevents the transmission of emetic signals to the vomiting center in the brainstem. The orodispersible film formulation allows rapid dissolution and absorption in the oral cavity for faster onset of action.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ondansetron orodispersible film once

What is Ondansetron orodispersible film once?

Ondansetron orodispersible film once is a 5-HT3 receptor antagonist drug developed by Chongqing University Cancer Hospital, indicated for Prevention of nausea and vomiting induced by chemotherapy, Prevention of postoperative nausea and vomiting, Prevention of radiation-induced nausea and vomiting.

How does Ondansetron orodispersible film once work?

Ondansetron blocks serotonin 5-HT3 receptors on chemoreceptor trigger zone and vagal afferent nerves to prevent nausea and vomiting.

What is Ondansetron orodispersible film once used for?

Ondansetron orodispersible film once is indicated for Prevention of nausea and vomiting induced by chemotherapy, Prevention of postoperative nausea and vomiting, Prevention of radiation-induced nausea and vomiting.

Who makes Ondansetron orodispersible film once?

Ondansetron orodispersible film once is developed and marketed by Chongqing University Cancer Hospital (see full Chongqing University Cancer Hospital pipeline at /company/chongqing-university-cancer-hospital).

What drug class is Ondansetron orodispersible film once in?

Ondansetron orodispersible film once belongs to the 5-HT3 receptor antagonist class. See all 5-HT3 receptor antagonist drugs at /class/5-ht3-receptor-antagonist.

What development phase is Ondansetron orodispersible film once in?

Ondansetron orodispersible film once is FDA-approved (marketed).

What are the side effects of Ondansetron orodispersible film once?

Common side effects of Ondansetron orodispersible film once include Headache, Constipation, Diarrhea, Fatigue, Dizziness.

What does Ondansetron orodispersible film once target?

Ondansetron orodispersible film once targets 5-HT3 receptor and is a 5-HT3 receptor antagonist.

Related